The Magnitude and Duration of *Clostridium difficile* Infection Risk Associated with Antibiotic Therapy: A Hospital Cohort Study

Kevin A. Brown¹, David N. Fisman¹, Rahim Moineddin², Nick Daneman³

¹ Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada, ² Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada, ³ Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

**Abstract**

Antibiotic therapy is the principal risk factor for *Clostridium difficile* infection (CDI), but little is known about how risks cumulate over the course of therapy and abate after cessation. We prospectively identified CDI cases among adults hospitalized at a tertiary hospital between June 2010 and May 2012. Poisson regression models included covariates for time since admission, age, hospitalization history, disease pressure, and intensive care unit stay. Impacts of antibiotic use through time were modeled using 4 measures: current antibiotic receipt, time since most recent receipt during a hospitalization, and duration of receipt. Over the 24-month study period, we identified 127 patients with new onset nosocomial CDI (incidence rate per 10,000 patient days [IR] = 5.86). Of the 4 measures, time since most recent receipt was the strongest independent predictor of CDI incidence. Relative to patients with no prior receipt of antibiotics in the last 30 days (IR = 2.95), the incidence rate of CDI was 2.41 times higher (95% confidence interval [CI] 1.41, 4.13) during antibiotic receipt and 2.16 times higher when patients had receipt in the prior 1–5 days (CI 1.17, 4.00). The incidence rates of CDI following 1–3, 4–6 and 7–11 days of antibiotic exposure were 1.60 (CI 0.85, 3.03), 2.27 (CI 1.24, 4.16) and 2.10 (CI 1.12, 3.94) times higher compared to no prior receipt. These findings are consistent with studies showing higher risk associated with longer antibiotic use in hospitalized patients, but suggest that the duration of increased risk is shorter than previously thought.

Citation: Brown KA, Fisman DN, Moineddin R, Daneman N (2014) The Magnitude and Duration of *Clostridium difficile* Infection Risk Associated with Antibiotic Therapy: A Hospital Cohort Study. PLoS ONE 9(8): e105454. doi:10.1371/journal.pone.0105454

**Introduction**

*Clostridium difficile* infection (CDI) is a hospital and community-acquired disease that especially impacts elderly hospitalized patients receiving antibiotics [1]. CDI incidence in North American hospitals has increased drastically in the last 30 years, and this has been hypothesized to be due to the emergence of new, hyper-virulent strains and to the ubiquity of antibiotic use among hospitalized patients [2]. In temperate countries, CDI has a seasonality that follows, with several months delay, that of seasonal prescribing of broad spectrum antibiotics and of pneumonia [3–5].

Antibiotic receipt represents the most important known risk factor for CDI; it is thought to induce CDI risk by denuding the gut of protective bacteria and increasing *C. difficile* spore germination [6,7]. Almost all classes of antibiotics have been found to increase CDI risk; certain classes including fluoroquinolones, cephalosporins and clindamycin are thought to have a more potent impact while others, such as tetracyclines, may not change CDI risk at all [8]. Several studies have followed patients for periods of 30 to 100 days post-admission and shown that a relatively elevated incidence of CDI exists for patients post-discharge [9–12]. Recent studies have used survival analysis incorporating time-varying antibiotic exposures and indicated that increased duration, number, and dosages of antibiotics were associated with increased risk [13,14]. Weighted cumulative exposure models build on survival analysis and stipulate that current risks may be considered as functions of past exposures [15], and may be used to explicitly and flexibly estimate the day-by-day CDI risk during and after antibiotic therapy. As such, our objective was to assess the degree to which risks associated with antimicrobial exposures both cumulate over the course of antimicrobial therapy and abate after cessation.

**Methods**

**Ethics Statement**

Study approval was obtained from the Research Ethics Board of Sunnybrook Health Sciences Centre who waived the need for patient consent because there was no contact with the patients and anonymity was assured.
Study Design and Participants
A cohort study design was used to assess the association of antibiotic exposure with the incidence of CDI among patients admitted to Sunnybrook hospital, a large acute care teaching hospital located in Toronto, Canada. The source cohort consisted of all patients over 18 years old, without a previous CDI diagnosis, and hospitalized in an acute care ward at Sunnybrook hospital in the June 1, 2010 to May 31, 2012 period and excluded time spent in the hospital’s psychiatry ward.

CDI Case Definition
*C. difficile* infected patients were prospectively identified by the Infection Prevention and Control (IPC) department via active surveillance during the study period. In accordance with the provincial surveillance definition [16], a CDI case was defined as any hospitalized patient with either: (a) laboratory confirmation of a positive toxin assay together with diarrhea, or (b) visualization of pseudomembranes on sigmoidoscopy, colonoscopy, or histopathology. For the purposes of surveillance, diarrhea was defined as two or more loose/watery bowel movements in a 24-hour period, which was unusual or different for the patient, and with no other recognized etiology. Among patients developing CDI, days after the first CDI infection were excluded from the at-risk set. Time at risk was restricted to that of hospitalized patients up until the beginning of symptoms of the first disease onset and excluded the first two days of patients’ hospital admissions (patients without a hospital exposure within the previous 4 weeks cannot be considered to have nosocomial acquisition in their first two days of admission according to the provincial CDI definition). Toxin assays at the hospital have been performed by polymerase chain reaction (PCR) since September 2009, which includes the entire study period.

For CDI cases, event time was the number of days from hospital admission to symptom onset, or positive toxin assay for rare cases in which symptom onset was missing. For non-cases, censoring time was the number of days from hospital entry until discharge, study termination, or death.

Antimicrobial Exposure Assessment
Patient antibiotic exposures were drawn from pharmacy dispensing records. We examined for daily receipt of any antibiotic but excluded exposure to metronidazole and oral vancomycin since these may be treatments for CDI. Daily antibiotic receipt was classified according to the Anatomical Therapeutic Chemical (ATC) Classification System, 17th edition [17]. Only antibiotic classes with a prevalence of at least 20 per 1,000 patient-days of follow-up (2%) were analyzed individually; preliminary analyses identified penicillins (ATC: J01C), cephalosporins/carbapenems (J01D), and fluoroquinolones (J01M) as meeting this criterion. We further subdivided penicillins into broad (J01CA, J01CG and J01CR) and narrow spectrum agents (J01CE and J01CF) and cephalosporins/carbapenems into 1st and 2nd generation cephalosporins (J01DB and J01DC), 3rd and 4th generation cephalosporins (J01DD and J01DE), and carbapenems (J01DH), for a total of 8 antibiotic classes that were analyzed individually. We also identified daily receipt of the following 6 infrequently prescribed classes of antibiotics: tetracyclines (J01A), nitrofurantoin (J01XE), sulfamidines and trimethoprim (J01E), macrolides and streptogramins (J01FA and J01FG), aminoglycosides (J01G), and lastly, clindamycin and other lincosamides (J01FF).

Using the antibiotic classes identified above, we developed two alternative measures of antibiotic exposure: (1) an index representing the number of distinct classes of antibiotics a patient received on a given day (classified as 0, 1 or ≥2), and (2) a categorical antimicrobial risk index based on Brown et al. [18] which classified patients according to whether they received a high risk antibiotic (defined as receipt of cephalosporins/carbapenems, fluoroquinolones, or clindamycin and other lincosamides), had received a medium risk antibiotic but not a high risk antibiotic (defined as penicillins, sulfonamides and trimethoprim, macrolides and streptogramins, or aminoglycosides), or had received no antibiotics or a low risk antibiotic only (defined as receipt of tetracyclines).

Modeling Time-Varying Antimicrobial Exposures
We created 4 variables based on patients’ unique antibiotic exposure histories: (1) current antibiotic receipt, which was dummy coded as 1 for days when a patient received an antibiotic, and 0 otherwise, (2) the time lapse since the most recent antibiotic use (in days), which was categorized as 0 (current use), 1–5, 6–30, >30 (including no use), (3) time lapse since the start of the first antibiotic exposure during a given hospitalization, which was categorized as 0–2, 3–6, 7–14, 15–30 and >30 (including no use), and (4) the duration of antibiotic use, categorized as 0 (no use), 1–3, 4–6, 7–11 and >11.

Other Risk Factors
Patient age, sex, hospital pharmacy record, and bed assignment, were obtained from electronic hospital administrative records. Infection pressure was derived by calculating the number of diagnosed infectious patients with CDI in each ward of the hospital at noon of each day using patient location records. The infectious period of a given diagnosed patient (which included cases and non-cases with non-nosocomial or recurrent disease) was defined as starting on the day after symptom onset to 14 days after the positive test associated with case detection. This is in keeping with Dubberke et al. [19] with the exception that the day of onset was excluded from disease pressure calculations so that new cases did not contribute disease pressure risk to themselves. We also measured the use of antacids (ATC: A02), laxatives (A06), feeding tube [20], and whether a patient had stayed in an intensive care unit (ICU).

Statistical Analysis
For bivariate analyses in which we compared characteristics of the at-risk period of cases with a 10% simple random sample of non-case patients (controls), two-sided p-values were assessed with Pearson’s chi-squared test for categorical variables and with the Wilcoxon rank-sum test for continuous variables. For the principal case-cohort analysis based on Poisson regression (models described below), which were used to measure unadjusted incidence rates and unadjusted and adjusted incidence ratios, we weighted all of the control patients’ follow-up times by 10 and all of the case patients’ follow up times by 1, so as to reflect rates from the original, complete, cohort, as per the Barlow method [21].

To estimate the impact of antibiotic exposures on CDI risk, we developed weighted Poisson regression models that aimed to predict the time elapsed from hospital admission to the occurrence of a first CDI infection. Our data was structured in counting process format with one record for each patient-day. For each of the 4 antibiotic exposure covariates, two models were fitted to the data. The 4 adjusted models included no covariates other than antibiotic exposures; incidence rate ratios were estimated using Poisson regression. The 4 adjusted models included 6 potential confounders: time since admission (modeled as a b-spline with knots at 5 and 15 days), patient age (classified as <45, 45 to <65, ≥65 years), sex, number of previous hospital admissions (classified as 0, 1, ≥2), patient-days of infection pressure in the past 10 days,
and ICU admission in the past 10 days. The number of adjustment factors was restricted in order to ensure at least 10 events per covariate [22], and the selection of covariates was based on established associations with CDI risk [13,23]. For the adjusted models, intra-patient correlation was accounted-for using generalized estimating equations [24]. Statistical fit for all models was assessed using Akaike’s Information Criterion [25].

Subsequently, we used the best fitting of the 4 antibiotic exposure covariates to determine risk associated with the two risk indexes and for each of the 8 antibiotic classes. For unadjusted and adjusted estimates of the antibiotic-specific risks, antibiotic exposure adjustment variables were derived which measured exposure to any other antibiotic without exposure to the antibiotic in question.

Analyses were conducted using R statistical software (v3.0.2); the glm and geeglm [26] functions were used for the unadjusted and adjusted statistical models, respectively. R statistical software analysis code is provided in Appendix S1.

Sensitivity Analyses

In order to assess the potential impact of uncertainty of diagnostic timing on the analyses, we conducted a sensitivity analysis using positive C. difficile PCR test date rather than symptom onset date to define the outcome timing. Also, because pre-admission antibiotic exposure information was not available, we conducted an additional sensitivity analysis excluding cases and patient time in the first 10 days of each hospitalization to investigate the impact of exposure history incompleteness.

Results

Description of Cohort

Over the two-year study period, and before exclusion of ineligible patients, a total of 47,241 patients were identified as having been admitted to Sunnybrook Health Science Centre (Figure 1). Of these, 412 were diagnosed with CDI; after exclusion of patients with recurrent or non-nosocomial CDI, and patients with onset of CDI while out of hospital, or within the first two days of an admission, 127 nosocomial case patients remained. After removal of ineligible non-case patients, the 10% control cohort selection consisted of 1,940 patients. The incidence of CDI in the cohort was 5.86 per 10,000 days of follow-up (127/2,169,978).

Demographic and Exposure Characteristics of Cases and Controls

The median age of cases (72.0) was almost 5 years older than that of controls (67.3, p = 0.14, Table 1). Cases had a higher rate of exposure to other symptomatic CDI patients in their own ward (median, 20 per 100 person-days versus 0 per 100 person-days, p = 0.12). About half (50.4%) of case patients spent time in the ICU during their risk period compared to 19.5% of controls (p < 0.001).

A larger proportion of case patients received antibiotics during their risk period relative to controls (86.6% vs 49.5%, p<0.001). The majority (71.7%) of cases received a cephalosporin class of antibiotic compared to 33.1% of controls (p<0.001). Similarly, penicillins and fluoroquinolones were more likely to be prescribed among case patients compared to controls. Among case patients, median symptom onset date was 9 days after admission (IQR: 5–17 days).

Risk Associated with Antibiotic Exposures

The incidence of CDI when patients received antibiotics was 8.43 per 10,000 days (64/75,959) compared to 4.47 (63/141,019) when patients did not receive antibiotics (Table 2); it follows that the incidence rate ratio (IRR) associated with current antibiotic exposure was 1.89 (95% confidence interval [CI] 1.33, 2.67). Adjustment for time since admission, patient age, sex, number of previous hospital admissions, disease pressure, and current or prior ICU admission reduced the IRR slightly, to 1.79 (95% CI 1.24, 2.59).

Among the 4 antibiotic exposure measures, the time since last antibiotic use was the most important independent predictor of CDI onset, and yielded a statistically significant improvement in the prediction of CDI onset (Δ adjusted AIC = −4.6). The incidence of CDI (per 10,000 days) was 2.95 when patients had received no antibiotics in the previous 30 days (reference), 8.43 when patients were currently receiving antibiotics (adjusted IRR: 2.41, 95% CI 1.41, 4.13), 8.12 when patients had recent receipt in the last 1–5 days (adjusted IRR: 2.16, 95% CI 1.19, 3.32), and
3.58 when patients had received antibiotics in the last 6–30 days (adjusted IRR: 0.98, 95% CI 0.48, 2.00, Figure 2).

The time elapsed since the start of the first antibiotic exposure in a given hospitalization also yielded an improved prediction of the timing of CDI onset (Δ adjusted AIC = −0.7). The observed association was highest 3–6 days (adjusted IRR = 3.10, 95% CI 1.73–5.54) and 7–14 days (adjusted IRR = 1.76, 95% CI 0.98–3.13) after the start of antibiotics. The duration of antibiotic exposure yielded a worse model fit relative to the adjusted model with current antibiotic use (Δ adjusted AIC = 5.1).

Sensitivity Analyses

For all remaining analyses including the sensitivity analyses and the investigation of antibiotic class-specific effects, we categorized antibiotic exposure history as receipt of antibiotics in the last 5 days (which included current receipt), or no receipt in the last 5 days. The adjusted risk was 2.35 (95% CI 1.53, 3.60) for patients that had received an antibiotic in the previous 5 days (Table 3). We conducted 2 different sensitivity analyses; neither impacted the estimated risk substantially. In the first sensitivity analysis, we considered the impact of restricting the dataset to follow-up ≥10 days after admission, so that complete information on antibiotic history was known for a larger proportion of patients. The adjusted IRR for risk extended 5 days beyond the end of antibiotic use was similar to that of the full cohort (2.23, 95% CI 1.21, 4.13). We also considered a sensitivity analysis in which we varied the assignment of CDI event date; when positive test date rather than symptom onset was used to define the outcome, the number of eligible cases increased from 127 to 130. The adjusted incidence rate for antibiotic use in the last 5 days was similar, at 2.79 (95% CI 1.47, 5.27).

Antibiotic Risk According to Antimicrobial Classes

In order to consider differences in the level of risk among antibiotic users, we considered risk among patients with exposure to various combinations of antibiotics and to specific antibiotics (Table 3). The adjusted risk associated with CDI was similar when patients either received a single class of antibiotic (IRR = 2.49, 95% CI 1.59, 3.92) or when patients received multiple classes of antibiotics (IRR = 2.09, 95% CI 1.23, 3.55). For our antibiotic risk

Table 1. Selected Characteristics of Case and Control Patients, Sunnybrook Hospital, Toronto, Canada, June 2010 to May 2012.

| Incident Cases | Controls | P value |
|---------------|----------|---------|
| (N = 127)     | (N = 1940) |         |
| N (%)         | N (%)    |         |

### Admissions

- 1: 76 (59.8) vs. 1494 (77.0) < 0.001
- 2: 30 (23.6) vs. 302 (15.6) < 0.001
- ≥3: 21 (16.5) vs. 144 (7.4) < 0.001

### ICU stay

- 64 (50.4) vs. 379 (19.5) < 0.001

### Antibiotic exposure

- Total: 110 (86.6) vs. 961 (49.5) < 0.001
- Penicillins: 38 (29.9) vs. 220 (11.3) < 0.001
- Broad-spectrum: 29 (22.8) vs. 191 (9.8) < 0.001
- Narrow-spectrum: 12 (9.4) vs. 43 (2.2) < 0.001
- Cephalosporins/carbapenems: 91 (71.7) vs. 642 (33.1) < 0.001
- 1st & 2nd generation: 44 (34.6) vs. 388 (20.0) < 0.001
- 3rd & 4th generation: 59 (46.5) vs. 326 (16.8) < 0.001
- Carbapenems: 11 (8.7) vs. 41 (2.1) < 0.001
- Fluoroquinolones: 49 (38.6) vs. 381 (19.6) < 0.001
- IV vancomycin: 28 (22.0) vs. 107 (5.5) < 0.001

### Other exposures

- Antacids (PPIs and H2 inhibitors): 96 (75.6) vs. 1268 (65.4) 0.024
- Laxatives: 91 (71.7) vs. 1187 (61.2) 0.024
- Feeding tube: 53 (41.7) vs. 263 (13.6) < 0.001

Abbreviations: PPI, proton pump inhibitor; ICU, intensive care unit; IQR, interquartile range.

* Equal to the number of patients diagnosed with CDI in the same ward as a given patient each day.

DOI: 10.1371/journal.pone.0105454.t001
| Antibiotic use on current day | CDI Cases | Follow-up | IR* | Unadjusted IRR | AdjustedΔ AICb IRR | Δ AICb |
|-------------------------------|-----------|-----------|-----|---------------|--------------------|--------|
| No                            | 63        | 141019    | 4.47| Reference     | Reference          |        |
| Yes                           | 64        | 79595     | 8.43| 1.89 (1.33, 2.67) | 1.79 (1.24, 2.59)  | 0      |
| Time since end antibiotic therapy (d) |          |           |     |               |                    |        |
| 0 (current receipt)           | 64        | 79595     | 8.43| 2.86 (1.73, 4.72) | 2.41 (1.41, 4.13)  |        |
| 1–5                           | 30        | 36950     | 8.12| 2.75 (1.56, 4.85) | 2.16 (1.17, 4.00)  |        |
| 6–30                          | 13        | 36288     | 3.58| 1.21 (0.60, 2.44) | 0.98 (0.48, 2.00)  |        |
| >30, or no antibiotic use     | 20        | 67781     | 2.95| Reference     | −9.5               | −4.6   |
| Time since start of first antibiotic (d) |          |           |     |               |                    |        |
| 0–2                           | 7         | 21060     | 3.32| 1.08 (0.47, 2.49) | 1.39 (0.56, 3.46)  |        |
| 3–6                           | 40        | 38007     | 10.52| 3.43 (2.11, 5.59) | 3.10 (1.73, 5.54)  |        |
| 7–14                          | 33        | 37530     | 8.79| 2.87 (1.72, 4.77) | 1.76 (0.98, 3.13)  |        |
| 15–30                         | 20        | 32313     | 6.19| 2.02 (1.13, 3.60) | 1.56 (0.84, 2.90)  |        |
| >30, or no antibiotic use     | 27        | 88068     | 3.07| Reference     | −14.6              | −0.7   |
| Cumulative duration of antibiotic use (d) |          |           |     |               |                    |        |
| 0 (no prior receipt)          | 20        | 67781     | 2.95| Reference     | Reference          |        |
| 1–3                           | 25        | 45201     | 5.53| 1.87 (1.04, 3.37) | 1.60 (0.85, 3.03)  |        |
| 4–6                           | 28        | 34596     | 8.09| 2.74 (1.55, 4.87) | 2.27 (1.24, 4.16)  |        |
| 7–11                          | 28        | 35968     | 7.78| 2.64 (1.49, 4.68) | 2.10 (1.12, 3.94)  |        |
| >11                           | 26        | 33432     | 7.78| 2.64 (1.47, 4.72) | −0.07              | 2.81 (1.39, 5.81) | 5.1    |

Abbreviations: AIC, Akaike’s Information Criterion; CDI, Clostridium difficile infection; CI, confidence interval; d, days; IR, incidence rate; IRR, incidence rate ratio.

*Incidence rate, per 10,000 patient-days.

Δ The difference in AIC relative to the reference model (current antibiotic use); negative numbers denote an improvement in fit. Δ AIC < −2 was considered a statistically significant improvement in fit at p < 0.05.

*Adjusted for time since hospital admission, age, sex, number of previous hospital admissions, infection pressure, and current or prior ICU admission.

doi:10.1371/journal.pone.0105454.t002
index variable, which was based on established associations of antibiotics with CDI risk, the adjusted risk was 1.79, (95%CI 1.24, 2.59) for medium-risk antibiotics and was 2.43 (95%CI 1.59, 3.74) for high-risk antibiotics.

For each of the 8 antibiotic classes and subclasses for which there was sufficient exposure for individual analysis (>2% of subcohort patient-time), we measured the risk of the given antibiotic taken alone or in combination with other antibiotics, relative to no antibiotic exposure. In adjusted analyses, all 3 of the most prescribed antimicrobial classes demonstrated similarly large hazard ratios. Of the subclasses, 3rd & 4th generation cephalosporins taken alone or in combination, had higher risk in comparison to other antibiotic classes (adjusted IRR = 3.40, 95%CI 2.02, 5.72).

Discussion

Our observational study of 127 CDI cases and 2 years of follow-up on patients at a large tertiary hospital found that: (1) in-hospital CDI risk was highest 3 to 14 days after the start of the first antibiotic course, (2) elevated CDI risk persisted for a period of 5 days after the end of antimicrobial therapy, and (3) patients with longer antibiotic courses were at higher risk of developing CDI than patients with shorter courses, but even short courses and single doses of antibiotics incur a substantial risk of inducing CDI.

Our study is the first to compare the duration of antibiotic use, time since antibiotic initiation, and time since antibiotic cessation as measures of CDI risk; our results showed that measuring the time since last antibiotic use is the most predictive metric for quantifying risk for a patient, whereby risk during and within 5 days of cessation was the most elevated. Antibiotic duration has already been shown to be more predictive than cumulative dosage for predicting CDI risk [13]; this study goes one step further and shows that time since cessation of antibiotics is a better predictor than antibiotic duration. Since colonization resistance is thought to be greatly diminished both during and for a period after the end of antibiotic use, our findings support the importance of this mechanism and reflect findings from animal and in vitro models of colonization resistance as it relates to CDI [27,28]. However, our study demonstrated substantially shorter impacts of antibiotic use on patient risk compared to previous empirical studies: in a case-control study of 337 patients with healthcare-associated CDI, risk was found to be relatively constant both during antibiotic use and for a period of 30 days after cessation [29], diminishing more than 30 days after the end of antimicrobial exposure. Our study population was restricted to inpatients that may have developed CDI more rapidly than outpatients and patients discharged from hospital. Lastly, although our findings show that risk is principally driven by time since antibiotic cessation, inferring from the low risk for 2 days after the start of antimicrobial use, our models provide empirical evidence that the incubation period of CDI is at least 48h [30].

A strength of this study was our use of a combination of analytic methods tailored to the study of nosocomial infections. Foundational texts in epidemiologic methods principally covered the use of logistic regression and survival analysis for the study of chronic diseases that develop over the course of many years [31,32]. As such, some of these methods may not be optimal for understanding nosocomial infections that develop rapidly over the course of days and hours from the time of hospital admission, and are driven by contagion [33,34]. In order to address these characteristics of nosocomial infections, our analyses were based on an extension of survival analysis that incorporated both weighted cumulative exposures to account for the time-sensitive nature of antibiotic effects [15], and disease pressure, to incorporate the impacts of contagion from patients with CDI [35]. Future analyses of infectious diseases transmitted by the fecal-oral route could attempt to quantify ingestion of disease-causing organisms [36]. Ignoring contagion not only leads to incorrect estimation of risk factors due to residual confounding and unaccounted spatial

Figure 2. The Magnitude and Duration of *Clostridium difficile* Infection Risk After Antibiotic Therapy, Sunnybrook Hospital, Toronto, Canada, June 2010 to May 2012. Among inpatients, the incidence of *Clostridium difficile* infection was highest in the period 3 to 14 days after the start of antibiotic therapy, during antibiotic therapy, and within 5 days of the end of antibiotic therapy. * Includes patients without any identified antibiotic use.
doi:10.1371/journal.pone.0105454.g002
| Exposure in the preceding 5d | CDI Cases | Follow-up | IR<sup>a</sup> | IR Ratio (95% CI) | Δ AIC<sup>b</sup> | IR Ratio (95% CI) | Δ AIC<sup>b</sup> |
|-----------------------------|-----------|-----------|----------------|------------------|----------------|------------------|----------------|
| **Any antibiotic**          |           |           |                |                  |                |                  |                |
| No                          | 33        | 104069    | 3.2            | Reference        | Reference      | Reference        | Reference      |
| Yes                         | 94        | 112909    | 8.3            | 2.63 (1.77, 3.90) | 0              | 2.35 (1.53, 3.60) | 0              |
| **Number of antibiotics**   |           |           |                |                  |                |                  |                |
| 0                           | 33        | 104069    | 3.2            | Reference        | Reference      | Reference        | Reference      |
| 1                           | 64        | 73593     | 8.7            | 2.74 (1.90, 4.17) | 2.49 (1.59, 3.92) | 2.49 (1.59, 3.92) | 2.49 (1.59, 3.92) |
| ≥2                          | 30        | 39316     | 7.6            | 2.41 (1.47, 3.95) | 1.6            | 2.09 (1.23, 3.55) | 1.6            |
| **Antibiotic risk index**   |           |           |                |                  |                |                  |                |
| None or low-risk            | 35        | 106396    | 3.3            | Reference        | Reference      | Reference        | Reference      |
| Medium-risk                 | 12        | 19256     | 6.2            | 1.89 (1.33, 2.67) | 1.79 (1.24, 2.59) | 1.79 (1.24, 2.59) | 1.79 (1.24, 2.59) |
| High-risk                   | 80        | 91326     | 8.8            | 2.66 (1.79, 3.96) | 2.1            | 2.43 (1.59, 3.74) | 1.3            |
| **Class of antibiotic<sup>d</sup>** |           |           |                |                  |                |                  |                |
| Penicillins                 | 24        | 25103     | 9.5            | 3.02 (1.78, 5.10) | 1.4            | 2.77 (1.56, 4.90) | 1.7            |
| Broad-spectrum              | 16        | 18876     | 8.5            | 2.67 (1.47, 4.86) | 2.0            | 2.39 (1.26, 4.53) | 2.3            |
| Narrow-spectrum             | 8         | 6857      | 11.7           | 3.68 (1.70, 7.97) | 1.1            | 3.64 (1.47, 9.00) | 1.5            |
| Cephalosporins              | 61        | 66330     | 9.2            | 2.90 (1.90, 4.43) | 20             | 2.07 (1.69, 4.32) | 0.2            |
| 1<sup>st</sup> & 2<sup>nd</sup> generation | 31    | 38508     | 8.0            | 2.54 (1.55, 4.15) | 1.9            | 2.36 (1.36, 4.10) | 2.3            |
| 3<sup>rd</sup> & 4<sup>th</sup> generation | 32    | 27092     | 11.8           | 3.72 (2.9, 6.06)  | −2.8           | 3.40 (2.02, 5.72) | −2.5           |
| Carbapenems                 | 6         | 5962      | 10.1           | 3.17 (1.33, 7.57) | 1.8            | 2.40 (0.93, 6.23) | 2.3            |
| Fluoroquinolones            | 24        | 30286     | 7.9            | 2.50 (1.48, 4.23) | 1.9            | 2.16 (1.26, 3.72) | 2.0            |
| IV vancomycin               | 16        | 11883     | 13.5           | 4.25 (2.34, 7.71) | −1.6           | 3.19 (1.62, 6.26) | 1.2            |

Abbreviations: AIC, Akaike’s Information Criterion; CDI, Clostridium difficile infection; CI, confidence interval; d, days; IR, incidence rate; IRR, incidence rate ratio.

<sup>a</sup> Incidence rate, per 10,000 patient-days.

<sup>b</sup> The difference in AIC relative to the reference model (receipt of any antibiotic in the previous 5 days): negative numbers denote an improvement in fit. Δ AIC < −2 was considered a statistically significant improvement in fit at p < 0.05.

<sup>c</sup> Adjusted for time since hospital admission, age, sex, number of previous hospital admissions, infection pressure, and current or prior ICU admission.

<sup>d</sup> Each antibiotic group was assessed in a separate model; the reference group for each model was no receipt of antibiotics in the last 5 days.

DOI: 10.1371/journal.pone.0105454.t003
clustering of cases, but also appears to have driven an overestimation of the risk associated with current or recent antibiotic exposure.

A limitation of our study was our lack of information on outpatient antimicrobial exposures prior to patient hospitalization, since our exposure free reference group used for calculating hazard ratios could have included patients exposed to antibiotics prior to admission. However, our findings were robust in sensitivity analyses considering subsets of patients with more prolonged hospitalization and therefore more complete antibiotic exposure histories. Further, our study lacked information on post-discharge C. difficile diagnoses. Considering discharged patients as censored surmounted this limitation, but means that our results are most generalizable to acute, hospital-onset CDI. Furthermore, clinical teams are aware of antimicrobial exposures which may prompt diagnostic testing for CDI [27], and this surveillance bias may lead to an overestimation of the risk associated with current antibiotic exposure. We had no data on C. difficile colonization status and timing of acquisition of the organism, which would be expected to influence the time lapse between antibiotic exposure and disease onset. Finally, our hospital information system lacked information on patient comorbidities and other healthcare exposures including discharges and outpatient visits to other hospitals in the region.

Antibiotic use is the most important risk factor for CDI, and a substantial amount of research has considered the risk of CDI associated with different antibiotic exposures. In this study of the association between antibiotic exposures and CDI risk in hospitalized adults, we focused on the timing of increased risk; we found that risk appears 3 days after the onset of antibiotic use, and continues for a period of 5 days after the end of antibiotics, and is relatively unimportant thereafter. Further research may consider how different antibiotics may induce different time-varying risks in order to differentiate antibiotic impacts and improve patient outcomes.

Supporting Information
Appendix S1 R Statistical Software Analysis Code For Tables and Poisson Regression Models. (TXT)

Author Contributions
Conceived and designed the experiments: KAB DNF RM ND. Performed the experiments: KAB ND. Analyzed the data: KAB DNF RM ND. Contributed reagents/materials/analysis tools: KAB RM. Wrote the paper: KAB DF ND. Drafted the manuscript: KAB ND. Critically revised the manuscript: DNF RM ND.

References
1. Kunst J, Chrischilles E, Pendergast J, Hervaldt L, Polgreen P (2011) Incidence of and risk factors for community-associated Clostridium difficile infection: A nested case-control study. BMC Infect Dis 11: 194.
2. Kelly CP, LiMonti JT (2008) Clostridium difficile—more difficult than ever. N Engl J Med 359: 1932–1940. doi:10.1056/NEJMra0707500.
3. Gilca R, Fortin E, Frenette C, Longtin Y, Goureau M (2012) Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada. Antimicrobial Agents Chemotherapy 56: 639–646. doi:10.1128/AAC.01411-11.
4. Polgreen PM, Yang M, Bohnett LC, Cavanaugh JE (2010) A time-series analysis of Clostridium difficile and its seasonal association with influenza. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 31: 382–387. doi:10.1086/631095.
5. Brown KA, Daneman N, Arora P, Moineddin R, Fisman DN (2013) The co-occurrence of pneumonia and influenza with Clostridium difficile infection in the United States, 1993–2008. Am J Epidemiol 177: 118–125. doi:10.1093/aje/kw3463.
6. Britton KA, Young VB (2012) Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 20: 313–319. doi:10.1016/j.trendsmicrob.2012.04.001.
7. Tancrède C (1992) Role of human microflora in health and disease. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 11: 1012–1015.
8. Delaney JAC, Dial S, Barkun A, Suissa S (2007) Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 13: 761–763. doi:10.3201/eid1305.061124.
9. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S (2008) Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. Can Med Assoc J 179: 767–772. doi:10.1503/cmaj.071812.
10. Chang HT, Kezouh D, Johnson S, Parada JP, Evans CT, et al. (2007) Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 28: 926–931. doi:10.1086/519178.
11. Dubberke ER, McMullen KM, Mayfield JL, Reske KA, Georgantopoulos P, et al. (2009) Hospital-associated Clostridium difficile infection: is it necessary to track community-onset disease? Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 30: 332–337. doi:10.1086/596004.
12. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA (2005) Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 26: 690–694. doi:10.1086/502602.
13. Stevens V, Dumntay G, Fine LS, Fisher SG, van Wijngaarden E (2011) Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis Off Publ Infect Dis Soc Am 53: 42–48. doi:10.1093/cid/cdr301.
14. Stevens V, van Wijngaarden E (2011) Ignoring the variability in timing of drug administrations attenuates hazard ratios. Am J Epidemiol 173: S272.
15. Abrahamowicz M, Beauchamp M-E, Sylvestre M-P (2012) Comparison of alternative models for linking drug exposure with adverse effects. Stat Med 31: 1014–1030. doi:10.1002/sim.4943.
16. Provincial Infectious Diseases Advisory Committee (2007) Best practices document for the management of Clostridium difficile in all health care settings protecting patients and staff. Toronto.
17. WHO Collaborating Centre for Drug Statistics Methodology, Folkehelseinstituttet (Norway) (2013) Guidelines for ATC classification and DDD assignment. Oslo. WHO Collaborating Centre for Drug Statistics Methodology: Norwegian Institute of Public Health. Available: http://www.whocc.no/archive/publications/2014guidelinespdf.pdf. Accessed 5 June 2014.
18. Brown KA, Khanauer N, Daneman N, Fisman DN (2013) Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection. Antimicrobial Agents Chemotherapy 57: 2326–2332. doi:10.1128/AAC.02176-12.
19. Dubberke ER, Reske KA, Olsen MA, McMullen KM, Mayfield JL, et al. (2007) Evaluation of Clostridium difficile-associated disease as a risk factor for C. difficile-associated disease. Arch Intern Med 167: 1092–1097. doi:10.1001/archinternmed.167.10.1092.
20. Bliss DJ, Johnson S, Savik K, Clabots CR, Willard K, et al. (1998) Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 129: 1012–1019.
21. Barlow WE, Ichikawa L, Ronner D, Izumi S (1999) Analysis of case-cohort designs. J Clin Epidemiol 52: 1163–1172.
22. Peduzzi P, Concordato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. I. Accuracy and precision of regression estimates. J Clin Epidemiol 48: 1503–1510.
23. Bignardi GE (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40: 1–15. doi:10.1016/S0195-6701(98)90019-6.
24. Hanley JA, Negassa A, Edwards MD dB, Forrester JE (2003) Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 157: 364–375.
25. Pan W (2001) Akaike’s information criterion in generalized estimating equations. Biometrics 57: 120–125.
26. Hojgaard S, Halkoek U, Yan J (2006) The R Package geepack for Generalized Estimating Equations. J Stat Softw 15/2: 1–11.
27. Jump RLP, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ (2011) Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemotherapy 55: 546–549. doi:10.1128/AAC.00839-10.
28. Baines SD, Crowther GS, Todhunter SL, Freeman J, Chilton CH, et al. (2013) Mixed infection by Clostridium difficile in an in vitro model of the human gut. J Antimicrob Chemother 68: 1139–1143. doi:10.1093/jac/dkt539.
29. Heugens MMP, Goorhuis A, Dekkers OM, Kuiper EJ (2012) Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 67: 742–748. doi:10.1093/jac/dkr300.
30. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 31: 431–455. doi:10.1086/651706.

31. Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ: 5–338.

32. Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II—The design and analysis of cohort studies. IARC Sci Publ: 1–406.

33. Schumacher M, Allignol A, Beyersmann J, Binder N, Wolkewitz M (2013) Hospital-acquired infections—appropriate statistical treatment is urgently needed! Int J Epidemiol. doi:10.1093/ije/dyt111.

34. Halloran ME, Struchiner CJ (1991) Study designs for dependent happenings. Epidemiology 2: 331–338.

35. Ajao AO, Harris AD, Roghmann M-C, Johnson JK, Zhan M, et al. (2011) Systematic review of measurement and adjustment for colonization pressure in studies of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and clostridium difficile acquisition. Infect Control Hosp Epidemiol 32: 481–489. doi:10.1086/650403.

36. Cherrie JW, Semple S, Christopher Y, Saleem A, Hughson GW, et al. (2006) How Important is Inadvertent Ingestion of Hazardous Substances at Work? Ann Occup Hyg 50: 693–704. doi:10.1093/annhyg/mel035.

37. Slimings C, Riley TV (2014) Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69: 881–891. doi:10.1093/jac/dkt477.

38. Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, et al. (2013) Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369: 1195–1205. doi:10.1056/NEJMoa1216064.